M&A Deal Summary

Relief Therapeutics Holding AG Acquires APR

On May 4, 2021, Relief Therapeutics Holding AG acquired life science company APR for 75M CHF

Acquisition Highlights
  • This is Relief Therapeutics Holding AG’s 2nd transaction in the Life Science sector.
  • This is Relief Therapeutics Holding AG’s largest (disclosed) transaction.
  • This is Relief Therapeutics Holding AG’s 1st transaction in Switzerland.

M&A Deal Summary
Date 2021-05-04
Target APR
Sector Life Science
Buyer(s) Relief Therapeutics Holding AG
Deal Type Add-on Acquisition
Deal Value 75M CHF

Target

APR

Balerna, Switzerland
APR is a pharmaceutical company, identifying, developing, and commercializing known molecules engineered with drug delivery systems in niche and rare diseases on a global basis. The pipeline includes products at different stage of development concentrated in 3 selected therapeutic areas: inherited metabolic recessive diseases, cancer supportive care and skin rare diseases. APR was founded in 1990 and is based in Balerna, Switzerland.

Search 200,626 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Relief Therapeutics Holding AG

Zurich, Switzerland
Category Company
Founded 2013
Sector Life Science
DESCRIPTION

Relief Therapeutics Holding AG is a clinical-stage biotechnology company with a portfolio of drug candidates derived from natural human origins. Its two most promising drug candidates are aviptadil for the treatment of sarcoidosis (already in Phase III) and low dose interleukin-6 (atexakin alfa) for the treatment of peripheral diabetic neuropathy (already in Phase II).

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 2 of 2
Country (Switzerland) 1 of 1
Year (2021) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-07-27 FirstString Research

Mount Pleasant, South Carolina, United States

FirstString Research, Inc. is a clinical-stage biotechnology company. FirstString Research's lead drug candidate, Granexin® gel (aCT-1), is a novel, proprietary peptide mimetic of the C-terminus of connexin43, which has been shown to play a fundamental role in processes that are critical to wound healing.

Buy -
Mergr

Product

Company

Legal